Clik here to view.
The risks of continuing to smoke after diagnosis, treatment for prostate cancer
An article just published in BJU International has further confirmed the risks associated with continuing to smoke cigarettes after initial diagnosis with, and treatment for, prostate cancer. According...
View ArticleClik here to view.
The optimization of risk assessment for management of prostate cancer
According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of...
View ArticleClik here to view.
Half of long-term erectile function (EF) loss after brachytherapy (BT) is due...
One of the most important things we patients want to know about any treatment is what kind of potency we can expect afterwards. Urinary and rectal dysfunctions are often measured and reported by...
View ArticleClik here to view.
Salvage treatment of recurrent, lymph node-positive prostate cancer in the...
The advent of imaging tests like the [11C]choline PET/CT scan and others have made it possible to identify, relatively early, the presence of one or more foci of recurrent prostate cancer after...
View ArticleClik here to view.
How much time is there to make decisions about treatment for low-risk patients?
In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 =...
View ArticleClik here to view.
Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!
A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical...
View ArticleClik here to view.
Using the modified poliovirus to treat prostate cancer
For the benefit of those who saw (or heard about but did not see) the “60 Minutes” program last night dealing with the use of modified poliovirus in the treatment of patients with recurrent...
View ArticleClik here to view.
Just how helpful is personalized genomic analysis anyway?
Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types —...
View ArticleClik here to view.
Optimal brachytherapy pre-treatment for intermediate-risk patients depends on...
Anthony D’Amico has been advocating breaking up the intermediate-risk category into “favorable” and “unfavorable,” and now offers yet another circumstance where the optimal treatment is different for...
View ArticleClik here to view.
CRPC, “personalized” medicine, and the science of whack a mole
We have known for decades that prostate cancer is an “evolutionary” cancer. In other words, clinically significant prostate cancer and prostate cancer-specific mortality are the consequence of a series...
View ArticleClik here to view.
Assessing the “value” of new drugs in the treatment of [prostate] cancer
Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities,...
View ArticleClik here to view.
Active surveillance under-used (back in 2010-2011)
A new research letter just published in JAMA Internal Medicine suggests that only about 12 percent or less of the men who are good candidates for active surveillance are actually being managed in that...
View ArticleClik here to view.
Radiation therapy may improve survival even when PSA ≥ 75 ml/ml
Sometimes, when patients originally present with very high PSA levels, a negative bone scan, and a negative CT scan, they are put on permanent androgen deprivation therapy (ADT) because the doctor...
View ArticleClik here to view.
Expectant management is really “coming of age” in the USA
An excellent new review article in CA: A Cancer Journal of Clinicians, along with a research letter just published in the Journal of the American Medical Association (JAMA) have provided us with an...
View ArticleClik here to view.
Standardizing outcome measures in management of advanced prostate cancer
The Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement has finally been able to pull together a set of standardized patient-centered outcomes...
View ArticleClik here to view.
Expectations and realities: are we really helping couples to cope...
A recent review in the journal Translational Andrology and Urology, which is reprinted on line on the Medscape Oncology web site, addresses the issue of “Couples-based interventions following prostate...
View ArticleClik here to view.
Low PSA, high Gleason score at diagnosis predicts very high risk
There have long been suggestions that men with high-risk disease who initially present with relatively low PSA levels (< 2.5 ng/ml) may be at higher than average risk for prostate cancer-specific...
View ArticleClik here to view.
A complete, sustained response of mCRPC to treatment with ABT-888
A newly published report in Frontiers in Oncology is likely to be of considerable interest to many patients currently battling progressive and advanced forms of prostate cancer … but we emphasize that...
View ArticleClik here to view.
White button mushroom powder and recurrent prostate cancer
A small Phase I clinical trial in just 36 patients, funded by the Mushroom Growers of Australia and North America, has suggested that powdered mushroom may have an effect on PSA levels of at least some...
View ArticleClik here to view.
Testosterone therapy and risk for prostate cancer (redux)
The question of whether long-term exposure to testosterone therapy is associated with a significant increase in risk for a diagnosis of prostate cancer (and particularly clinically significant or...
View Article